Melanocortin Receptor 4 - Pipeline Review, H2 2020

Summary

Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Melanocortin Receptor 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 2 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Genetic Disorders, Musculoskeletal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones and Immunology which include indications Obesity, Type 2 Diabetes, Cachexia, Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Lipodystrophy (Lipoatrophy), Metabolic Syndrome, Multiple Sclerosis, Prader-Willi Syndrome (PWS), Rheumatoid Arthritis and Smith-Magenis Syndrome (Chromosome 17p11.2 Deletion Syndrome).

Furthermore, this report also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
• The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope